NO20085331L - Pyrazolo[1,5-A]pyrimidiner som CDK-inhibitorer - Google Patents

Pyrazolo[1,5-A]pyrimidiner som CDK-inhibitorer

Info

Publication number
NO20085331L
NO20085331L NO20085331A NO20085331A NO20085331L NO 20085331 L NO20085331 L NO 20085331L NO 20085331 A NO20085331 A NO 20085331A NO 20085331 A NO20085331 A NO 20085331A NO 20085331 L NO20085331 L NO 20085331L
Authority
NO
Norway
Prior art keywords
pyrazolo
pyrimidines
cdk inhibitors
compounds
cdk
Prior art date
Application number
NO20085331A
Other languages
English (en)
Norwegian (no)
Inventor
Amin A Nomeir
Ronald J Doll
Timothy J Guzi
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of NO20085331L publication Critical patent/NO20085331L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20085331A 2006-05-22 2008-12-19 Pyrazolo[1,5-A]pyrimidiner som CDK-inhibitorer NO20085331L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80257706P 2006-05-22 2006-05-22
PCT/US2007/011991 WO2007139732A1 (en) 2006-05-22 2007-05-21 Pyrazolo [1, 5-a] pyrimidines as cdk inhibitors

Publications (1)

Publication Number Publication Date
NO20085331L true NO20085331L (no) 2009-02-19

Family

ID=38544151

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20085331A NO20085331L (no) 2006-05-22 2008-12-19 Pyrazolo[1,5-A]pyrimidiner som CDK-inhibitorer

Country Status (18)

Country Link
US (1) US20070275963A1 (es)
EP (1) EP2027127A1 (es)
JP (1) JP2009538304A (es)
KR (1) KR20090019796A (es)
CN (1) CN101495481A (es)
AR (1) AR061072A1 (es)
AU (1) AU2007268083A1 (es)
BR (1) BRPI0712016A2 (es)
CA (1) CA2653076A1 (es)
EC (1) ECSP088906A (es)
IL (1) IL195238A0 (es)
MX (1) MX2008014824A (es)
NO (1) NO20085331L (es)
PE (1) PE20080071A1 (es)
RU (1) RU2008150419A (es)
TW (1) TW200817404A (es)
WO (1) WO2007139732A1 (es)
ZA (1) ZA200809796B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101903396A (zh) * 2007-11-07 2010-12-01 先灵公司 新的细胞周期关卡调节剂和它们与关卡激酶抑制剂的联合应用
BR112012005550A2 (pt) * 2009-09-11 2015-09-08 Cylene Pharmaceuticals Inc lactamas heterociclo-substituídas farmaceuticamente úteis
US9180127B2 (en) 2009-12-29 2015-11-10 Dana-Farber Cancer Institute, Inc. Type II Raf kinase inhibitors
US8916557B2 (en) * 2011-04-19 2014-12-23 Bayer Intellectual Property Gmbh Substituted 4-Aryl-N-phenyl-1,3,5-triazin-2-amines
EP2723746A1 (en) 2011-06-22 2014-04-30 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
WO2013059634A1 (en) 2011-10-20 2013-04-25 The Regents Of The University Of California Use of cdk9 inhibitors to reduce cartilage degradation
AU2012340200B2 (en) 2011-11-17 2017-10-12 Dana-Farber Cancer Institute, Inc. Inhibitors of c-Jun-N-Terminal Kinase (JNK)
WO2014063068A1 (en) 2012-10-18 2014-04-24 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
WO2014063061A1 (en) 2012-10-19 2014-04-24 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
ES2946360T3 (es) 2012-12-07 2023-07-17 Vertex Pharma Pirazolo[1,5-a]pirimidinas útiles como inhibidores de ATR quinasa para el tratamiento de enfermedades de cáncer
WO2014143240A1 (en) 2013-03-15 2014-09-18 Vertex Pharmaceuticals Incorporated Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase
US8969360B2 (en) 2013-03-15 2015-03-03 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
WO2014143241A1 (en) 2013-03-15 2014-09-18 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
JP6491202B2 (ja) 2013-10-18 2019-03-27 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド サイクリン依存性キナーゼ７（ｃｄｋ７）の多環阻害剤
ES2676734T3 (es) 2013-10-18 2018-07-24 Syros Pharmaceuticals, Inc. Compuestos heteroatómicos útiles para el tratamiento de enfermedades proliferativas
RU2687276C2 (ru) 2013-12-06 2019-05-13 Вертекс Фармасьютикалз Инкорпорейтед Соединения, пригодные для использования в качестве ингибиторов atr киназы
US20160319368A1 (en) * 2013-12-17 2016-11-03 Csir A Method for Identification of Anti-HIV Human miRNA Mimics and miRNA Inhibitors and Anti-HIV Pharmaceutical Compounds
LT3152212T (lt) 2014-06-05 2020-05-11 Vertex Pharmaceuticals Inc. Radioaktyviai žymėti 2-amino-6-fluor-n-[5-fluor-piridin-il]- pirazolo[1,5-a]pirimidin-3-karboksamido junginio dariniai, naudingi kaip atr kinazės inhibitoriai, minėto junginio gamybos būdas ir jo skirtingos kietos formos
SG11201610500WA (en) 2014-06-17 2017-01-27 Vertex Pharma Method for treating cancer using a combination of chk1 and atr inhibitors
CA3000633C (en) 2014-10-14 2023-10-03 The Regents Of The University Of California Use of cdk9 and brd4 inhibitors to inhibit inflammation
EP3236959A4 (en) 2014-12-23 2018-04-25 Dana Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
CA2978518C (en) * 2015-03-27 2023-11-21 Nathanael S. Gray Inhibitors of cyclin-dependent kinases
AU2016276963C1 (en) 2015-06-12 2021-08-05 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
CA2996978A1 (en) 2015-09-09 2017-03-16 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
CA3000684A1 (en) 2015-09-30 2017-04-06 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of dna damaging agents and atr inhibitors
RU2633032C1 (ru) * 2016-05-23 2017-10-12 Общество с ограниченной ответственностью "Новые научные технологии" Новые ингибиторы серин-треониновых киназ, в том числе для лечения онкологических заболеваний и туберкулеза
CN111566100B (zh) * 2018-02-12 2023-10-27 恩瑞生物医药科技（上海）有限公司 嘧啶类化合物、其制备方法及其医药用途
CN112996790B (zh) 2018-10-30 2023-11-03 克洛诺斯生物公司 用于调节cdk9活性的化合物、组合物和方法
CN111393447B (zh) * 2020-05-14 2021-01-15 苏州信诺维医药科技有限公司 一种嘧啶并吡唑类化合物、其制备方法及应用
CN117567460A (zh) * 2022-08-08 2024-02-20 明慧医药（杭州）有限公司 一种前药化合物及其制备方法和用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE362474T1 (de) * 2002-09-04 2007-06-15 Schering Corp Pyrazolo(1,5-a)pyrimidine als hemmstoffe cyclin- abhängiger kinasen
US7119200B2 (en) * 2002-09-04 2006-10-10 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
EP1537116B1 (en) * 2002-09-04 2010-06-02 Schering Corporation Pyrazolopyrimidines suitable for the treatment of cancer diseases
US7605155B2 (en) * 2002-09-04 2009-10-20 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
TWI421078B (zh) * 2005-10-06 2014-01-01 Merck Sharp & Dohme 關卡激酶抑制劑及其用途
WO2007041712A1 (en) * 2005-10-06 2007-04-12 Schering Corporation Pyrazolopyrimidines as protein kinase inhibitors

Also Published As

Publication number Publication date
CA2653076A1 (en) 2007-12-06
AU2007268083A1 (en) 2007-12-06
CN101495481A (zh) 2009-07-29
RU2008150419A (ru) 2010-09-20
PE20080071A1 (es) 2008-02-11
US20070275963A1 (en) 2007-11-29
IL195238A0 (en) 2009-08-03
TW200817404A (en) 2008-04-16
ZA200809796B (en) 2009-11-25
BRPI0712016A2 (pt) 2011-12-27
AR061072A1 (es) 2008-07-30
WO2007139732A1 (en) 2007-12-06
EP2027127A1 (en) 2009-02-25
ECSP088906A (es) 2008-12-30
JP2009538304A (ja) 2009-11-05
MX2008014824A (es) 2008-12-01
KR20090019796A (ko) 2009-02-25

Similar Documents

Publication Publication Date Title
NO20085331L (no) Pyrazolo[1,5-A]pyrimidiner som CDK-inhibitorer
NO20082091L (no) Nye pyrazolopyrimidiner som syklinavhengige kinaseinhibitorer
PH12015500666A1 (en) Pyrazolopyrimidine jak inhibitor compounds and methods
NO20053144L (no) Chk-, Pdk- og Akt-inhibitorpyrimidiner, deres fremstilling og anvendelse som famasoytiske midler.
MX2009011355A (es) Nuevas pirazolopirimidinas como inhibidores de quinasas dependientes de ciclinas.
MY169791A (en) Substituted pyrazolo [1,5-a] pyrimidine compounds as trk kinase inhibitors
MY188338A (en) Imidazotriazines and imidazopyrimidines as kinase inhibitors
WO2004078682A3 (en) Cyclic compounds and compositions as protein kinase inhibitors
BRPI0720270B8 (pt) compostos 4-fenil-6-(2,2,2-triflúor-1-fenil etoxi) pirimidina, composição e forma de dosagem sólida
MX2009003734A (es) Pirazolopirimidinas como inhibidor de cinasas dependientes de ciclina.
MX2009003185A (es) Pirazolopirimidinas como inhibidores de lipido cinasa pi3k.
SG132683A1 (en) Imidazopyrazine tyrosine kinase inhibitors
MX2009011950A (es) Derivados de pirimidina y composiciones como inhibidores de cinasa c-kit y pdgfr.
WO2006106326A8 (en) Substituted heterocycles and their use as chk1, pdk1 and pak inhibitors
MX2009003733A (es) Pirazolopirimidinas como inhibidores de quinasas dependientes de ciclina.
WO2009097287A9 (en) Compounds and compositions as kinase inhibitors
NO20074431L (no) Pyrrolopyrimidiner nyttige som proteinkinaseinhibitorer
SG170828A1 (en) Deazapurines useful as inhibitors of janus kinases
GT201000082A (es) Derivados de pirrolo [2,3-d] pirimidina como inhibidores de proteinas quinasas b
NO20082092L (no) Pyrazolopyrimidiner som proteinkinaseinhibitorer
BR112012010041A2 (pt) derivados de imidazo [1,2-b] piridazina e seu uso como inibidores de pde10
MX2009004771A (es) Compuestos heteroaril triciclicos utiles como inhibidores de janus cinasa.
MX2009006690A (es) Aminopirimidinas utiles como inhibidores de proteinas cinasas.
WO2008045267A3 (en) Pyrazolopyrimidines as cyclin dependent kinase inhibitors
WO2007087283A3 (en) Thiophene-carboxamides useful as inhibitors of protein kinases

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application